• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»probiotics

OLLY launches Precise Probiotics: Is targeted gut health the next big wellness trend

By Pallavi Madhiraju on April 24, 2026   Pharma & Biotech  

OLLY launches Precise Probiotics: Is targeted gut health the next big wellness trend

Explore how OLLY’s Precise Probiotics could reshape gut health trends and personalized wellness. Find out what this means for consumers today.

Why Pendulum Therapeutics is taking its microbiome platform beyond metabolic health with Mayo Clinic

By Pallavi Madhiraju on April 11, 2026   Pharma & Biotech  

Why Pendulum Therapeutics is taking its microbiome platform beyond metabolic health with Mayo Clinic

Pendulum Therapeutics has expanded its Mayo Clinic collaboration into women’s health and dermatology. Read what this could mean for microbiome medicine.

Is Biocodex’s Fullify the first probiotic to challenge GLP-1 drugs in the consumer weight-loss space?

By Pallavi Madhiraju on January 30, 2026   Pharma & Biotech  

Is Biocodex’s Fullify the first probiotic to challenge GLP-1 drugs in the consumer weight-loss space?

Biocodex launches Fullify, a gut-brain axis probiotic for appetite control. Find out what this means for weight loss, microbiome science, and the supplement industry.

Recent Posts

  • Can Servier’s $2.65bn Edgewise deal reshape the muscular dystrophy drug race?
  • Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
  • Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
  • Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
  • Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
  • Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens
  • Why Aphranel’s EU MDR approval could sharpen competition in CaHA dermal fillers
  • Oricell’s ASCO 2026 liver cancer data put GPC3 CAR-T back in the spotlight
  • Can Lilly turn Hanmi’s sonefpeglutide into the next long-acting GLP-2 rare disease bet?
  • Can enicepatide and petrelintide help Genentech build a differentiated obesity franchise?
  • Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?
  • Why Tempus AI’s Lens upgrade matters for precision oncology drug development
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes